for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

PYC Therapeutics Ltd

PYC.AX

Latest Trade

0.14AUD

Change

0.00(0.00%)

Volume

74

Today's Range

0.14

 - 

0.14

52 Week Range

0.11

 - 

0.19

As of on the Australian Stock Exchange Ltd ∙ Minimum 15 minute delay

Pricing

Previous Close
0.14
Open
0.14
Volume
74
3M AVG Volume
12.37
Today's High
0.14
Today's Low
0.14
52 Week High
0.19
52 Week Low
0.11
Shares Out (MIL)
3,180.93
Market Cap (MIL)
461.23
Forward P/E
--
Dividend (Yield %)
--

Next Event

PYC Therapeutics Ltd Annual Shareholders Meeting

Latest Developments

更多

Pyc Therapeutics FY Revenues From Ordinary Activities Up 22%

PYC Therapeutics Appoints CEO In U.S.

PYC Therapeutics Gets FDA Response On Orphan Drug Designation Request

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About PYC Therapeutics Ltd

PYC Therapeutics Limited is an Australia-based drug-development company, which offers ribonucleic acid (RNA) therapeutics to meet unmet needs in disease. The Company has RNA targeted therapeutics design capabilities to deliver technology based on cell penetrating peptides (CPPs). The Company develops a pipeline of therapies, including three preclinical stage programs, which are focused on inherited eye diseases and preclinical discovery efforts, which are focused on neurodegenerative diseases. The Company’s lead drug candidate, VP-001 is designed to treat Retinitis pigmentosa 11 (RP11). The second lead drug candidate VP-002, which is focused on treating autosomal dominant optic atrophy (ADOA) and PYC-001 drug candidate to treat diabetic retinopathy. Its preclinical, clinical, regulatory and corporate operations are based in San Diego, California. The Company's discovery and laboratory operations are located in Australia.

Industry

Business Services

Contact Info

Harry Perkins Institute, 6 Verdun St

NEDLANDS, WAS

6009

Australia

+61.8.61510992

https://pyctx.com/

Executive Leadership

Alan Tribe

Chairperson of the Board

Douglas Huey

Chief Executive Officer

Kevin R. Hart

Chief Financial Officer, Company Secretary

Rohan Hockings

Director, Chief Strategy Officer

Sahm Nasseri

Director, Chief Executive Officer of PYC’s US Operations

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
142.28
Price To Book (MRQ)
8.70
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
1.38
LT Debt To Equity (MRQ)
1.02
Return on Investment (TTM)
-45.24
Return on Equity (TTM)
-41.64

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up